*JANUARY 28, 2021 UPDATE* The announced buprenorphine guidelines discussed below have not gone into effect. US DHHS’ announcement itself noted that the action was still subject to review. Recent news reports have stated that the proposed guidelines are being withdrawn for further evaluation. Board staff will provide further updates when available.
FRIDAY, JANUARY 15, 2021
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ANNOUNCES NEW GUIDELINES FOR THE PRESCRIBING OF BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. On January 14, 2021, the US Department of Health and Human Services announced the issuance of new guidance concerning buprenorphine prescribed and administered for the treatment of opioid use disorder. These changes are intended to make treatment services “more accessible for people most at risk of overdose.” US DHHS’ new practice guidelines exempt physicians from certain certification requirements needed to prescribe buprenorphine for opioid use disorder treatment. Under the new guidelines:
More information, including a link to the US DHHS guidelines, is found here: https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html